Chlorobutyl (also listed as cholorbutyl in legacy trade literature), bromobutyl, and nitrile rubber stoppers with ETFE/FEP lamination and silicone coating are supplied for pharmaceutical primary packaging in injection vial, oral liquid, tablet/capsule, granule, and lyophilization formats. Dimensional configurations follow ISO 8362 for 13 mm, 20 mm, and 32 mm neck sizes, with solid plug, slotted lyophilisation, and two-leg/three-leg vented forms. The halogenated butyl grades provide the primary closure function for parenteral drug products; nitrile is restricted to non-parenteral or selected oral/granule applications where solvent and lipid resistance outweigh extractable and gas-barrier limitations. ETFE and FEP films on product-contact surfaces isolate the elastomer from the formulation, and a polydimethylsiloxane-based silicone layer on the body and flange reduces cap insertion friction and needle penetration force. The commercial phrase “silicon coating” is understood here as a cured silicone film, not elemental silicon. Regulatory certification is typically supported by USP <381>, USP <382>, Ph. Eur. 3.2.9, ISO 8871-1, and FDA 21 CFR 177.2600 for indirect food-contact rubber articles. Product codes in supplier documentation generally use the sequence [elastomer grade]-[film type]-[silicone option]-[ISO 8362 size]; a bromobutyl–ETFE–silicone–20 mm configuration is a representative code architecture rather than a universal industry model designation.

What Differentiates Fluoropolymer-Laminated Halobutyl Stoppers from Uncoated Elastomer Closures?

The principal distinction is the presence of an ETFE or FEP film bonded to the product-contact face, which prevents direct contact between the elastomer and the active pharmaceutical ingredient. In uncoated halogenated butyl closures, extractable compounds such as oligomers, vulcanization residues, zinc oxide, and process antioxidants can migrate under aggressive formulation conditions; ETFE and FEP films reduce this migration by two to five-fold in model solvent extraction studies when measured by total organic carbon per ISO 8871-2. The film does not eliminate leachables from the edges or uncoated areas, so seal design and flange compression must be maintained within 20–35% compression to avoid exposing the elastomer core. ETFE has a continuous service temperature of approximately 150–180 °C, while FEP is generally rated at 200 °C but has lower crystallinity and may deform when exposed to steam sterilisation cycles beyond 121 °C for 30 min if not laminated onto a dimensionally stable substrate. Fluoropolymer lamination also reduces drug sorption for lipophilic compounds such as diazepam, nitroglycerin, and certain peptides; uncoated halobutyl can absorb 1–5% of low-molecular-weight hydrophobic APIs from dilute aqueous solution, whereas ETFE-laminated closures typically show sorption below 0.5% under identical conditions. Compared with platinum-cured silicone rubber closures, halogenated butyl grades provide approximately an order of magnitude lower oxygen permeability and lower water vapour transmission, while nitrile offers improved solvent resistance at the cost of higher gas permeability. These comparisons are drawn from supplier technical bulletins and peer-reviewed packaging interaction literature; published data for this exact multi-layer configuration is limited for biologics with complex formulations.

Compression Set, Moisture Vapour Transmission, and Extractables Profiles Across Elastomer Grades

The table below summarises representative values for chlorobutyl, bromobutyl, and nitrile elastomer grades used in pharmaceutical closures. The values are compiled from supplier technical data sheets, polymer science literature, and pharmacopeial test method training data; they are not single-lot release specifications. Where a formulation falls outside these ranges, the closure manufacturer should be required to provide batch-specific data against the appropriate test standard.

The data indicate that nitrile rubber is unsuitable for injectable primary packaging where low oxygen permeability and low aqueous extractables are critical quality attributes. Bromobutyl demonstrates marginally lower permanent set and lower oxygen permeability than chlorobutyl because the bromine substituent participates more efficiently in vulcanization reactions, yielding a tighter network density. The residual unsaturation in nitrile contributes to higher gas permeability and greater extractable content under extraction, while providing superior resistance to aliphatic solvents and some vegetable-oil-based liquid formulations. For oral granules and tablets where oxygen ingress is less critical but solvent exposure may occur, nitrile can be selected, provided that extractables data are generated and toxicological risk assessment is completed per ICH Q3D and USP <1664>.

Production-scale compression molding of halogenated butyl closures on automatic presses with 250–400 t clamping force requires preform weight control within ±1.5% to maintain Shore A hardness within ±3 points across a batch. Cure cycles of 3–8 min at 160–180 °C are common for zinc oxide/resole systems; post-curing at 150–160 °C for 60–120 min reduces the volatile monomer burden and stabilizes compression set. For bromobutyl compounds, the brominated isobutylene-isoprene elastomer responds to a wider range of cure accelerators, but excess accelerator can raise extractable thiuram and carbamate levels above the limits set by USP <381>. Injection molding of nitrile closures uses screw L/D ratios of 18:1–24:1, barrel temperatures of 120–160 °C, and mold temperatures of 140–170 °C; this process achieves higher throughput but requires more complex runner and gate design to prevent jetting, burn marks, and shear-induced porosity at the flange-to-plug transition. Lamination of ETFE or FEP film onto the elastomer surface is typically performed by heat-assisted bonding after molding, with film tension and surface corona/plasma preparation monitored to prevent delamination. Silicone coating is applied by atomized spray or tumbling with a polydimethylsiloxane emulsion at a cured film mass of 0.05–0.2 mg/cm². On high-speed inspection lines, silicone thickness variability above ±20% relative standard deviation produces variable needle insertion force and can cause false rejection during machine vision checks for film defects.

When Nitrile Rubber Replaces Halobutyl in Non-Parenteral Oral and Granule Closure Systems

Nitrile rubber should be considered only when the closure will not contact aqueous injectable formulations under terminal sterilisation or extended storage. In oral liquid, granule, tablet, and capsule packaging, the polymer’s resistance to oils, fatty acids, and alcohols reduces swelling that would otherwise degrade the seal force of halogenated butyl closures. However, this substitution is not equivalent: nitrile has higher oxygen permeability and higher aqueous extractables, and it can impart taste/odour to high-surface-area powder formulations if a fluoropolymer or polyolefin liner is not present. The closure’s compression set is also more sensitive to low-temperature conditioning; at -20 °C, nitrile may show a 10–20% increase in tension-relaxation loss relative to bromobutyl, requiring an increased residual seal force specification if cold-chain storage is used. In comparison with chlorobutyl/bromobutyl products, nitrile closures typically require additional leachables screening by GC-MS and LC-MS under USP <1663> because nitrile formulations contain plasticizers, processing aids, and antiozonants that are not present in medical-grade halogenated butyl compounds. For oral solid-dose bottles, a nitrile closure with FEP liner and silicone coating is generally adequate; for injectable use, it is contraindicated in most regulatory submissions because its oxygen barrier and extractable profile cannot meet compendial limits for aqueous parenteral packaging.

Silicone-Coated Bromobutyl Formulations for Low-Temperature Aseptic Processing

Silicone coating is not a structural barrier but a tribological surface treatment. In bromobutyl stoppers for aseptic filling lines, the cured polydimethylsiloxane layer lowers the static and dynamic coefficient of friction from approximately 0.7–1.0 for uncoated elastomer to 0.2–0.4 against borosilicate glass and cyclic olefin polymer vials, permitting consistent bowl feeding and orientation. The coating thickness is controlled gravimetrically rather than by dry film gauge because the elastomer surface is irregular; typical additions are 0.05–0.2 mg/cm² of cured silicone. Excess silicone increases particle burden in visible/subvisible particle testing, so final closure specifications include particle counts in filtered water per USP <788> or ISO 8871-1. Silicone-coated bromobutyl closures are used for low-temperature aseptic storage because silicone does not become brittle at temperatures down to -40 °C, while an uncoated elastomer surface may adhere to the vial neck during cold-line handling and cause insertion failures. The main process risk is silicone migration onto the vial neck and sealing surface, which can reduce container closure integrity if the capping head applies excessive residual seal force. Validation studies therefore measure residual seal force across a range of capping torques and confirm dye ingress per USP <1207> or helium leak rates below 6 × 10⁻⁸ Pa·m³/s after closure.

Container closure integrity validation for these stoppers follows USP <1207> and ISO 8871-1 for aqueous parenteral preparations. For lyophilization, vented bromobutyl stoppers with ETFE film are partially seated in the open position; the slot geometry provides a defined sublimation path, and the stopper is fully seated under vacuum or nitrogen backfill. Residual moisture of the lyophilized cake is a function of chamber pressure and shelf temperature, not the stopper alone, but closure water vapour transmission must be below the product stability requirement. A bromobutyl closure with 0.4–1.2 g·mm/m²/day MVTR is preferred over nitrile for lyophilized injectables because post-lyophilisation moisture ingress can degrade the cake at storage RH above 60%. For oral liquid and granule containers, closures are often specified with FEP liner and a lower silicone level to prevent odour contribution. Tablet/capsule bottles with induction-seal liners use the elastomer closure as an outer seal retainer; the elastomer does not contact the drug directly, so the main requirement is torque retention and dimensional recovery after repeated opening cycles.

Chemical compatibility data for these closures are generated according to ISO 8871-2 extraction and USP <1663> leachables protocols. Commonly tested model formulations include water for injection at pH 2–12, ethanol/water mixtures at 5–50% ethanol, polysorbate 80 solutions at 0.1–1.0%, and glycocholate/lecithin simulated intestinal media for oral products. Halogenated butyl grades show acceptable compatibility with a broad range of aqueous and weakly lipophilic APIs, but strong organic solvents such as N,N-dimethylacetamide and some lipid emulsions can swell the elastomer and increase extractables. ETFE-laminated closures withstand aggressive formulations better than uncoated closures but the film edge, pierced needle apertures, and elastomer–glass interface remain potential migration zones. Nitrile closures demonstrate low swelling in aliphatic and aromatic hydrocarbon-containing oral liquid formulas but may leach phthalate-free ester plasticizers in high-alcohol media; extractables testing should therefore be conducted in the actual formulation or a justified surrogate. Configurations include solid plug stoppers for liquid vials, lyophilisation stoppers with two or three legs and an open position for sublimation, and continuous-thread closures with elastomer liners for oral liquid bottles. Dimensional specifications follow ISO 8362-1 for vial stoppers and ISO 8362-6 for freeze-drying closures; flange thickness, plug diameter, and overall height are defined by the vial neck geometry. For 20 mm injection vial stoppers, the plug diameter is typically 20.0–20.8 mm to produce an interference fit with the glass neck under an aluminium crimp cap. Actual dimensions vary by supplier and should be verified against the specific vial manufacturer. The presence of ETFE/FEP film on the product-contact face increases the effective plug stiffness; compression force must be compensated during capping to avoid excessive residual seal force or flange distortion. Published data for this specific combination of chlorobutyl/bromobutyl/nitrile with ETFE/FEP and silicone coating is limited for biologics; users should perform formulation-specific leachable studies rather than rely on generic material declarations.